Not only for caregivers: intranasal glucagon for severe hypoglycaemia in a simulation study

Acta Diabetol. 2022 Nov;59(11):1479-1484. doi: 10.1007/s00592-022-01952-6. Epub 2022 Aug 11.

Abstract

Aims: To evaluate: (i) the propensity of paediatrics and emergency medicine residents to select different therapeutic options and (ii) the speed and administration success in a high-fidelity simulation of severe hypoglycaemia in a child with type 1 diabetes (T1DM).

Methods: In this single-centre high-fidelity simulation study, 51 paediatrics or emergency medicine residents were exposed to a scenario of severe hypoglycaemia in a T1DM child attending an ambulatory setting, before and after a training on the preparation and administration of both injectable and IN glucagon. Time for drug delivery and its effectiveness were collected.

Results: Before training, 45.1% of participants chose to administer injectable glucagon, 43.1% intravenous glucose solution, 5.9% intranasal (IN) glucagon, and 5.9% took no action. Administration was successful in 74% of injectable glucagon, 33.3% intravenous glucose solution, and 22.7% IN glucagon. After training, 58.8% of participants chose IN and 41.2% injectable glucagon, with 100% of successful administrations for IN glucagon and 90.5% for injectable glucagon. Time to successful administration was shorter for IN than injectable glucagon (23 ± 10 vs. 38 ± 7 s, p < 0.0001).

Conclusions: IN glucagon is an easy and effective option for severe hypoglycaemia treatment, with an almost zero possibility of failure provided that adequate training is imparted.

Keywords: Adolescents; Children; Hypoglycaemia; Intranasal glucagon; Simulation; Type 1 diabetes.

MeSH terms

  • Blood Glucose
  • Caregivers
  • Child
  • Diabetes Mellitus, Type 1* / drug therapy
  • Glucagon
  • Glucose
  • Humans
  • Hypoglycemia* / drug therapy
  • Hypoglycemia* / etiology
  • Insulin

Substances

  • Blood Glucose
  • Insulin
  • Glucagon
  • Glucose